{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"14"}],"units":"Participants"}],"description":"DLT was defined as all treatment-emergent adverse events (TEAEs) or abnormal laboratory values that met the protocol-defined DLT criteria, including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","groups":[{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Dose Escalation - Schedule A: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.045 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Dose Escalation - Schedule A: IMGN632 0.045 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.09 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"Dose Escalation - Schedule A: IMGN632 0.09 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.18 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Dose Escalation - Schedule A: IMGN632 0.18 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.3 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Dose Escalation - Schedule A: IMGN632 0.3 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.45 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Dose Escalation - Schedule A: IMGN632 0.45 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG006","title":"Dose Escalation - Schedule B: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.03 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG007","title":"Dose Escalation - Schedule B: IMGN632 0.03 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.06 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG008","title":"Dose Escalation - Schedule B: IMGN632 0.06 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety population included all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs)","type":"SECONDARY","unitOfMeasure":"Participants"}